KCNN4 and epilepsy: Several reports indicated that the blockade of KCa3.1 could represent a candidate approach for epilepsy treatment [60, 73], due to its ability to impair sustained Ca2+ entry in microglia during elevated neuronal activity and by shifting the phenotype of microglia towards an anti-inflammatory neuroprotective status [74, 75].